Managing hypertension in patients with type 2 diabetes mellitus

被引:17
作者
Dobesh, Paul P. [1 ]
机构
[1] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharm Practice, Omaha, NE 68198 USA
关键词
diabetes mellitus; drug use; hypertension; hypotensive agents; patient information; pharmacists; protocols; rational therapy;
D O I
10.2146/ajhp050385
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. Current guideline recommendations for effective strategies to optimize the treatment of patients with concomitant hypertension and type 2 diabetes mellitus are reviewed. Summary. Current estimates indicate that 20 million people in the United States have diabetes, 90-95% of whom have type 2 diabetes mellitus. Type 2 diabetes mellitus is associated with an increased risk of premature death from cardiovascular disease (CVD), stroke, and end-stage renal disease. Hypertension is an extremely common comorbidity in patients with type 2 diabetes mellitus. The coexistence of hypertension in patients with type 2 diabetes is particularly destructive because of the strong linkage of the two conditions with CVD, stroke, progression of renal disease, and diabetic nephropathy. Current guidelines, including those issued by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National Kidney Foundation, and the American Diabetes Association, provide evidence-based recommendations for the treatment of hypertension in patients with type 2 diabetes mellitus. However, studies indicate that guidelines are not widely followed. Therefore, the beneficial effects of appropriate hypertension treatment observed in clinical trials are often not recognized in clinical practice. Pharmacists are ideally positioned to help improve guideline implementation and patient outcome. Conclusion. Pharmacists must become more vigilant about following current guidelines for the treatment of patients with concomitant hypertension and type 2 diabetes mellitus. Strategies such as patient education and medication assessment can help to optimize care for these patients and slow the progression to diabetic nephropathy.
引用
收藏
页码:1140 / 1149
页数:10
相关论文
共 101 条
[1]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[2]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[3]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[4]  
[Anonymous], 1991, JAMA, V265, P3255
[5]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[6]  
[Anonymous], 2004, AM J KIDNEY DIS S1
[7]  
[Anonymous], HEART DIS STROK STAT
[8]  
[Anonymous], 2004, DIABETES CARE, DOI DOI 10.2337/DIACARE.27.5.1240-A
[9]  
Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083
[10]  
Arauz-Pacheco Carlos, 2004, Diabetes Care, V27 Suppl 1, pS65